Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Justin Fraser

Neurological Surgery Lexington, KY Medical Doctor

NPI 1427215094 CMS profile 200446

800 Rose St, Ms 106, Lexington, KY 40536

Open in the dashboard

General payments

$9,573

58 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$601,043 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Justin Fraser of Lexington, KY is reported in the CMS Open Payments database as having received $9,573 across 58 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $601,043 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 69th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $292 4
2023 General $1,990 24
2022 General $1,060 8
2021 General $43 1
2020 General $2,422 2
2019 General $3,767 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Fraser
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Justin Fraser were reported at $0. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Justin Fraser Neurological Surgery median Middle half National median
2019 $3,767 $582 $138–$3,006 $163
2020 $2,422 $294 $76–$2,174 $114
2021 $43 $387 $105–$2,432 $132
2022 $1,060 $542 $139–$2,989 $149
2023 $1,990 $534 $145–$2,697 $160
2024 $292 $574 $155–$3,046 $164
2025 $0 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Penumbra, Inc. $4,546 17 payments
  2. Medical Device Business Services, Inc. $1,500 16 payments
  3. Stryker Corporation $1,204 8 payments
  4. MicroVention, Inc. $986 3 payments
  5. Viz.Ai, Inc. $440 4 payments
  6. Qapel Medical Inc $262 1 payment
  7. Imperative Care, INc $223 2 payments
  8. Medtronic USA, Inc. $164 2 payments
  9. IRRAS USA, Inc. $111 1 payment
  10. DePuy Synthes Sales Inc. $68 1 payment
  11. Other $70 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Travel and Lodging $3,786 10 payments
  2. Food and Beverage $3,192 46 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,400 1 payment
  4. Consulting Fee $195 1 payment
Products named General payments · program years 2019–2024
  1. Penumbra System Neurointervention $2,780 5 payments
  2. Artemis Neurosurgery $2,744 6 payments
  3. FLOWGATE $1,004 3 payments
  4. WEB $986 3 payments
  5. EMBOGUARD $651 2 payments
  6. Viz.AI LVO $440 4 payments
  7. Penumbra System Neurointervention $302 3 payments
  8. ZOOM 88-T LARGE DISTAL PLATFORM $223 2 payments
  9. Artemis Neurosurgery $156 1 payment
  10. Pipeline $151 1 payment
  11. Other $673 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

79

Median for Neurosurgery: 83

Drug cost

$6,532

Median for Neurosurgery: $872

Branded share of claims

81%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 14 $6,162
Clopidogrel Clopidogrel Bisulfate Brand 50 $334
Prednisone Generic 15 $36

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$88,413

Medicare's payments for the services billed

Medicare patients

188

Average age 71

Services billed

624

106 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 39%
Diabetes 37%
COPD 36%
Depression 34%
Heart failure 26%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record